Obicetrapib Tablets Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 10 mg; 10 mg + ezetimibe 10 mg

Reference Brands: Ubeslo, Evlarco (with ezetimibe) — NewAmsterdam Pharma / Menarini

Obicetrapib is a once-daily CETP inhibitor that lowers LDL cholesterol. The European Commission approved it in September 2026 as Ubeslo, and with ezetimibe as Evlarco. It is not yet approved in the US. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers, API makers and licensees preparing for patent expiry.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Obicetrapib Tablets? List it or send an offer →

Product Description:

Obicetrapib blocks cholesteryl ester transfer protein (CETP), which moves cholesterol from HDL particles into LDL and other particles. Earlier CETP inhibitors raised HDL but did little for LDL and were dropped. Obicetrapib is more potent and lowers LDL cholesterol substantially as well as apolipoprotein B and lipoprotein(a), at a dose of 10 mg once a day.

The European Commission approved obicetrapib on 21 September 2026, its first approval anywhere, for adults with primary hypercholesterolaemia (familial and non-familial) or mixed dyslipidaemia whose LDL is not controlled. It comes alone as Ubeslo and as a fixed-dose tablet with ezetimibe 10 mg as Evlarco, to be used with a statin or where a statin is not tolerated. NewAmsterdam Pharma developed it; Menarini markets it in Europe. It is not yet approved in the US.

Sourcing and licensing notes. Obicetrapib is patented and there is no generic. European launches are only starting, so supply outside the EU depends on import permits and the originator's release plans. We handle authorised-supply enquiries and connect developers and licensees interested in the molecule and its ezetimibe combination ahead of patent expiry.

How Obicetrapib Tablets is supplied today, and licensing ahead of patent expiry

Obicetrapib Tablets is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Obicetrapib Tablets, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Obicetrapib Tablets supply →

Back to Listing